San Francisco, CA, April 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SourcingLink.net, Inc. (SNET), a San Francisco, CA
based company, announced today that it entered into an exclusive, worldwide licensing agreement with NanoSmart Pharmaceuticals, Inc
(NanoSmart) for the right to use NanoSmart's Anti-Nuclear Antibody (ANA)-targeted drug delivery technologies to develop and
commercialize chemotherapy drug formulations for veterinary oncology.
The National Cancer Institute estimated that as many as 12 million pets are diagnosed with cancer each year. The pet cancer
therapeutics market, according to Global Insights [source: https://gminsights.wordpress.com/tag/pet-cancer-therapeutics-market-size/] is projected
to exceed a revenue of $300 million by 2024, with a compound annual growth rate of 10% over 2017-2024. In addition, the
Comparative Oncology Program of the National Cancer Institute is designed to “gain a better understanding of the biology of cancer
and improve the assessment of novel treatments for humans by treating pet animals with naturally-occurring cancers.” [source: NCI
Center for Cancer Research: https://ccr.cancer.gov/research]
SourcingLink.net stated, "We are pleased to have licensed the application of NanoSmart's tumor-targeting technologies to improve
the safety and quality of treatments for animals suffering from cancer and other diseases. This is a significant extension of our
oncology product portfolio into animal health care to address the growing need for improved pet cancer therapies that can improve
outcomes and extend lifespan.”
The license includes broad access to NanoSmart’s proprietary drug delivery approaches, including ANA-targeted nanoparticles, for
the purpose of developing veterinary oncology drug products. Under the terms of the agreement, NanoSmart will receive restricted
common shares of SNET stock, an upfront fee, an annual maintenance fee, and a high single-digit royalty on net sales of
formulations that incorporate NanoSmart's intellectual property. Dr. James Smith, President of NanoSmart, stated, "This additional
license agreement demonstrates the value and broad-applicability of our drug delivery platform technologies. The development of
products for this market will also support SNET’s and NanoSmart’s mutual goal to provide new and affordable therapeutic options to
those suffering from this devastating disease. We look forward to supporting the SNET team to develop and commercialize these novel
products."
About SourcingLink.net
SourcingLink.net, Inc. ("SNET") is a pioneering oncology company dedicated to developing, manufacturing and commercialization of
therapeutics. SNET licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an
extracorporeal device. SourcingLink.net prides itself for having a world-class Advisory Board that keeps the
Company leadership in the forefront of developing technologies in cancer research, biotechnology and healthcare.
SourcingLink.net is currently engaging in research and development of therapeutics for oncology. SourcingLink.net is
committed to its core corporate mission and values of highest U.S. Pharma Code of Conduct standards of behavior for being in
compliance with the laws, regulations, company directives and guidance.
About NanoSmart Pharmaceuticals, Inc.
NanoSmart® Pharmaceuticals is a privately-held California corporation that is developing nanoparticle drug delivery platforms
that utilize anti-nuclear antibody (ANA) to target existing drug therapies to areas of necrosis present in virtually all solid
cancer tumors.
Forward-looking Statements:
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements, which contain words such as "expect", "believe" or "plan", by their nature address matters
that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than
those expressed in our forward-looking statements. We do not undertake to update our forward-looking
statements.
For additional Information, please contact at: One Sansome Street, Suite 3500 San Francisco, CA 94104 Phone: 415-869-1038 Fax: 415-946-8801 email: info@sourcinglink.net website: www.sourcinglink.net